Anafranil (clomipramine) is a prescription-only medication from a class of drugs called tricyclic antidepressants (TCAs). These drugs derive their name from the three rings that make up their chemical structure. This medication works by increasing the amount of serotonin and norepinephrine in the body—two neurotransmitters that, when increased, may help reduce anxiety and behaviors associated with obsessive compulsion.

What Mental Health Conditions Are Treated with Anafranil?

Anafranil is prescribed by psychiatrists to address obsessive compulsive thoughts and behaviors in children, teens, and adults. This medication may help control the thoughts and repetitive behaviors that accompany OCD; however, it is not intended as a cure for the condition. Typically people experiencing obsessive compulsive behaviors also seek treatment from a trained therapist or mental health professional.

Medication and Dosage FAQs

Important Information to Consider Before Use

Within the first few months of treatment, this medication may cause an increase in suicidal thoughts and actions in children, teenagers, and young adults. Similar effects may be observed if the dose is changed. People who have a family history of bipolar issues may be at a higher risk for developing thoughts of suicide. Pay close attention to any sudden or severe changes in mood, thoughts, feelings, or behavior. Call your doctor if any symptoms cause you to worry.

Older antidepressants like Anafranil have been linked with heart attack in people of any age. If you have or have ever had heart disease, heart failure, irregular heartbeat, heart attack, high or low blood pressure, brain damage, stroke, urinary problems, overactive thyroid, narrow-angle glaucoma, schizophrenia, bipolar issues, seizures, or tumors on your adrenal glands, you should talk to your doctor about these medical conditions before you take this drug. Tell your doctor if you currently have or have ever experienced alcohol addiction. Mention any serious reactions you may have had to other similar medications.

If you are taking other prescription drugs or supplements, you should check with your doctor or pharmacist before taking Anafranil. This drug may interact with other medications or supplements, including MAOIs, antihistamines, other antidepressants, antacids, antifungal creams and medications, sleeping pills, antipsychotics, vitamins, minerals, high blood pressure medications, herbal products, and more.

Considerations During Use

Anafranil, along with other TCAs, carries significant warnings of which to be aware. If you are prescribed this drug, make sure your doctor and/or pharmacist discusses the following information with you:

Possible Side Effects

If you experience serious or severe side effects from Anafranil, you should call your doctor. Your doctor will help you decide if the benefits of this medication outweigh the risks of using it. Serious side effects of this drug may include:

Less serious side effects from taking this medication may include:

How to Safely Withdraw

Do not stop taking Anafranil abruptly as your body may have become accustomed to the medication. Slowly tapering off of this medication will help reduce the occurrence and severity of withdrawal symptoms. Always talk to your doctor before reducing or discontinuing this medication. Possible symptoms of withdrawal include:

Discuss any withdrawal symptoms you experience with your doctor.

References:

  1. Citizens Commission on Human Rights International. (2012). The side effects of common psychiatric drugs. Retrieved from http://www.cchrint.org/pdfs/The_Side_Effects_of_Common_Psychiatric_Drugs.pdf
  2. Drugs.com. (2014). Anafranil. Retrieved from http://www.drugs.com/mtm/anafranil.html
  3. Medline Plus. (2014). Clomipramine. Retrieved from http://www.nlm.nih.gov/medlineplus/druginfo/meds/a697002.html
  4. RxList. (2012). Anafranil. Retrieved from http://www.rxlist.com/anafranil-drug.htm
  5. United States Food and Drug Administration. (2012). Medication guide: Anafranil. Retrieved from http://www.fda.gov/downloads/drugs/drugsafety/ucm085910.pdf

Page content reviewed by James Pendleton, ND.